Analysts Offer Predictions for SMMT Q2 Earnings

Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Summit Therapeutics in a report released on Wednesday, June 11th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($0.09) for the quarter. Leerink Partnrs currently has a "Strong Sell" rating on the stock. The consensus estimate for Summit Therapeutics' current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Summit Therapeutics' Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.37) EPS.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01.

A number of other brokerages also recently commented on SMMT. The Goldman Sachs Group raised their target price on shares of Summit Therapeutics from $37.00 to $41.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen raised shares of Summit Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. Jefferies Financial Group set a $44.00 price target on shares of Summit Therapeutics and gave the stock a "buy" rating in a research note on Friday, April 25th. JMP Securities reaffirmed a "market outperform" rating and set a $40.00 price target on shares of Summit Therapeutics in a research note on Monday, June 2nd. Finally, Citigroup raised shares of Summit Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $23.00 to $35.00 in a research note on Wednesday, March 26th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.09.

Summit Therapeutics Trading Down 1.9%

Shares of SMMT stock opened at $19.78 on Monday. The company's fifty day simple moving average is $23.68 and its 200-day simple moving average is $20.94. Summit Therapeutics has a 52 week low of $6.78 and a 52 week high of $36.91. The company has a market cap of $14.69 billion, a PE ratio of -70.64 and a beta of -1.06.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Golden State Wealth Management LLC grew its holdings in Summit Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 1,502 shares of the company's stock worth $29,000 after acquiring an additional 751 shares in the last quarter. National Bank of Canada FI acquired a new position in Summit Therapeutics during the 4th quarter worth $30,000. CWM LLC grew its holdings in Summit Therapeutics by 3,455.3% during the 1st quarter. CWM LLC now owns 1,671 shares of the company's stock worth $32,000 after acquiring an additional 1,624 shares in the last quarter. Steward Partners Investment Advisory LLC grew its holdings in Summit Therapeutics by 56.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,503 shares of the company's stock worth $45,000 after acquiring an additional 900 shares in the last quarter. Finally, AlphaQuest LLC acquired a new position in Summit Therapeutics during the 1st quarter worth $49,000. 4.61% of the stock is owned by institutional investors and hedge funds.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.